(RTTNews) - Sanofi S.A. (SNYNF ... the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases.

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...